Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- Status
- TERMINATED
- Phase
- PHASE1
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
- Status
- TERMINATED
- Phase
- PHASE2
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
- Status
- UNKNOWN
- Phase
- NA